Participants of group with combination of sugammadex 1 mg per kg and 50 micrograms per kg neostigmine were compared with that of neostigmine 50 micrograms per kg alone group for the main outcome of reversal of moderate neuromuscular block caused by vecuronium.

To compare the efficacy and safety of 1 mg/kg sugammadex combining with 50 g/kg neostigmine versus 50 g/kg neostigmine alone as reversal agent for a moderate neuromuscular block induced by vecuronium:A Randomized control study. - Randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/11/098138

Enrollment

Registered

2025-11-27

Start date

Unknown

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: neostigmine 50 micrograms per kg: To compare the time required for adequate reversal with 50 microgram per kg neostigmine alone as a reversal agent for reversal of vecuronium induced s

Eligibility

Inclusion criteria

Inclusion criteria: Age 18 to 60yr Patient willing to give informed consent. ASA 1-2 Patients undergoing elective sugery under general anaesthesia .

Exclusion criteria

Exclusion criteria: age less than 18 yrs or more than 60 yrs ASA3 patients patients undergoing emergency surgery patients having allergy to drugs

Design outcomes

Primary

Measure	Time frame
To compare adequate reversal of neuromuscular blockage recovery of the patient .Timepoint: To compare time required for adequate reversal of neuromuscular blockage recovery of the patient observed every 20 seconds with Train of Four and till 1 hour post surgery	—

Secondary

Measure	Time frame
To know the side effectsTimepoint: observed for 1 hour post surgery	—

Countries

India

Contacts

Public ContactDr Yathish S K

Bangalore medical college and research institute Bangalore

skyathish86@gmail.com7338595885

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026